Press Releases

 
Press Releases
Date Title and Summary View
Oct 8, 2015 SALT LAKE CITY, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new clinical outcomes and clinical utility data for myPath® Melanoma will be featured at the American Society of Dermatopathology (ASDP) 52nd meeting being held Oct. 8 to 11, 20...
Oct 7, 2015 SALT LAKE CITY, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostat...
Oct 5, 2015 SALT LAKE CITY, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that there will be seven poster presentations featured at American Society for Human Genetics (ASHG) meeting being held Oct. 6 to 10, 2015 in Baltimore, Md. "At Myriad, we are passion...
Oct 1, 2015 SALT LAKE CITY and ZURICH, Switzerland, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that Jan Schlüchter, Ph.D., has joined the Company as chief commercial officer (CCO) of Myriad Genetics GmbH, effective...
Sep 24, 2015 SALT LAKE CITY, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced three poster presentations that will be featured at the 40th European Society for Medical Oncology (ESMO) meeting being held Sept. 25 to 29, 2015 in Vienna, Austria. The presentations i...
Sep 14, 2015 SALT LAKE CITY, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:20 a.m. EDT on September 18, 2015, at the Grand Hyatt in New York City, New York. The presentation will be availa...
Sep 9, 2015 SALT LAKE CITY, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today presented two posters on its myPlan® Lung Cancer prognostic test at the International Association for the Study of Lung Cancer (IASLC) 16TH World Conference on Lung Cancer being held in Denver, Colo. The first study showed that the myPlan Lung Cance...
Sep 2, 2015 SALT LAKE CITY, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that it will host an Investor Day in New York City on Sept. 14, 2015. At the event, members of the Myriad executive management team will discus...
Sep 1, 2015 SALT LAKE CITY, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), announced that Elena Hitraya M.D., Ph.D., has joined the Company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She will report to Bernie Tobin, president of Crescendo Bioscience...
Aug 13, 2015 SALT LAKE CITY, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer. This decision...
Page: FirstPrevious ...
5
... NextLast
= add release to Briefcase